erlotinib hydrochloride has been researched along with idelalisib in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (idelalisib) | Trials (idelalisib) | Recent Studies (post-2010) (idelalisib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 412 | 46 | 401 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | idelalisib (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 0.0314 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.571 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.571 | |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | 1.577 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 2.5293 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 1.0202 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.2781 | |
| DNA-dependent protein kinase catalytic subunit | Homo sapiens (human) | 6.7 | |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 | Homo sapiens (human) | 2.6985 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Mus musculus (house mouse) | 1.302 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, EP; Overley, CW; Ratermann, KL; Stamatkin, C | 1 |
1 other study(ies) available for erlotinib hydrochloride and idelalisib
| Article | Year |
|---|---|
Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gene Expression; Humans; Inhibitory Concentration 50; Isoenzymes; Lung Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Purines; Pyrimidinones; Quinazolinones; Triazines | 2015 |